Edition:
United States

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

2.95USD
4:00pm EDT
Change (% chg)

$-0.05 (-1.67%)
Prev Close
$3.00
Open
$3.00
Day's High
$3.03
Day's Low
$2.92
Volume
117,305
Avg. Vol
128,891
52-wk High
$4.06
52-wk Low
$1.95

Latest Key Developments (Source: Significant Developments)

Acelrx Pharmaceuticals Q2 loss per share $0.29
Tuesday, 1 Aug 2017 07:05am EDT 

Aug 1 (Reuters) - Acelrx Pharmaceuticals Inc :Acelrx Pharmaceuticals reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.29.Q2 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S.Qtrly total revenue $2.7 million versus $4.5 million.  Full Article

AcelRx Pharmaceuticals reports successful outcome of Zalviso phase 3 IAP312 study on device functionality
Tuesday, 1 Aug 2017 07:00am EDT 

Aug 1 (Reuters) - Acelrx Pharmaceuticals Inc :Acelrx Pharmaceuticals reports successful outcome of zalviso phase 3 IAP312 study on device functionality.Acelrx Pharmaceuticals- in study, 2.2% of patients experienced zalviso device error, which was statistically less than 5% limit specified in objectives​.Acelrx Pharmaceuticals Inc- ‍none of the device errors resulted in an over-dosing event in study​.Acelrx Pharmaceuticals- ‍Zalviso shown to be well tolerated in study, with nausea, hypotension, vomiting representing most commonly reported adverse events​.Acelrx Pharmaceuticals Inc- ‍a total of 5 patients experienced serious adverse events, but all were considered unrelated to study drug by investigators​.Acelrx Pharmaceuticals - intend to submit results, together with earlier phase 3 studies, as part of resubmission of nda to fda by end of 2017​.  Full Article

Acelrx Pharmaceuticals appoints Raffi Asadorian CFO
Wednesday, 19 Jul 2017 07:00am EDT 

July 19 (Reuters) - Acelrx Pharmaceuticals Inc -:Acelrx Pharmaceuticals appoints Raffi Asadorian as chief financial officer.Acelrx Pharmaceuticals Inc - ‍appointment of Raffi Asadorian as chief financial officer, effective August 16, 2017​.Acelrx Pharmaceuticals Inc - ‍asadorian most recently served as chief financial officer at Amyris​.  Full Article

Acelrx Pharmaceuticals updates on notification from U.S. FDA
Wednesday, 7 Jun 2017 06:34am EDT 

June 7 (Reuters) - Acelrx Pharmaceuticals Inc ::U.S. FDA notified co that it no longer plans to hold an advisory committee meeting in connection with its review of NDA for Dsuvia.Decision does not alter PDUFA goal date for completion of review of NDA, which remains October 12, 2017 - SEC filing.  Full Article

Acelrx Pharmaceuticals files for mixed shelf of up to $150 mln
Monday, 5 Jun 2017 05:16pm EDT 

June 5 (Reuters) - Acelrx Pharmaceuticals Inc ::Acelrx Pharmaceuticals Inc files for mixed shelf of up to $150.0 million - sec filing.  Full Article

Acelrx Pharmaceuticals CFO Timothy Morris resigns
Monday, 5 Jun 2017 06:44am EDT 

June 5 (Reuters) - Acelrx Pharmaceuticals Inc :Acelrx Pharmaceuticals - on June 2, CFO Timothy E. Morris notified co of his resignation from all positions with co effective immediately - SEC filing.Acelrx Pharmaceuticals - ‍Vincent Angotti, co's chief executive officer, has been appointed to act as interim chief financial officer of co​ - SEC filing.  Full Article

AcelRx Pharmaceuticals reports Q1 total revenue $3.1 million
Monday, 8 May 2017 04:01pm EDT 

May 8 (Reuters) - AcelRx Pharmaceuticals Inc :AcelRx Pharmaceuticals reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.34.Q1 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.AcelRx Pharmaceuticals - As of March 31, AcelRx had cash, cash equivalents and investments of $72.3 million, compared to $80.3 million at December 31, 2016.Q1 total revenue $3.1 million versus $3.0 million.  Full Article

AcelRx Pharma says DSUVIA resulted in 3-point reduction in pain intensity within 60 minutes of administration
Thursday, 6 Apr 2017 07:00am EDT 

AcelRx Pharmaceuticals Inc : AcelRx Pharmaceuticals presenting comprehensive DSUVIA clinical trial results at ASRA's annual regional anesthesiology and acute pain medicine meeting . AcelRx Pharma -DSUVIA may have benefit as non-invasive analgesic modality in certain settings requiring short-term treatment of acute moderate-to-severe pain . AcelRx Pharmaceuticals Inc- no statistical separation was observed between active and placebo-controlled groups for dsuvia .AcelRx Pharmaceuticals - in emergency department study, DSUVIA resulted in a 3-point reduction in pain intensity within 60 minutes of administration.  Full Article

European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil
Tuesday, 28 Mar 2017 07:00am EDT 

Acelrx Pharmaceuticals Inc : European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil 30 mcg tablet (ARX-04) for moderate-to-severe acute pain .Acelrx expects an opinion on MAA from committee for medicinal products for human use (CHMP) in first half of 2018.  Full Article

Acelrx Pharmaceuticals Q4 loss per share $0.21
Thursday, 2 Mar 2017 04:01pm EST 

Acelrx Pharmaceuticals Inc : Acelrx Pharmaceuticals reports fourth quarter and year end 2016 financial results . Q4 loss per share $0.21 . Q4 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S . Qtrly total revenue $6.4 million versus $1.7 million .Q4 revenue view $3.7 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Acelrx Pharmaceuticals Q2 loss per share $0.29

* Acelrx Pharmaceuticals reports second quarter 2017 financial results and provides corporate update